Sigma Planning’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
Other funds holding NTLA
Sigma Planning's NTLA Position: Q3 2026 in Review
Sigma Planning increased its Intellia Therapeutics (NTLA) stake by 7.4% in Q3 2026, buying an estimated $9.39K and bringing the position to 10,892 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #1288.
Sigma Planning first reported a position in NTLA in Q2 2025 and has held it in 3 quarters since. The position peaked at $172K in Q2 2026. 239 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.
- Sigma Planning held 10,892 shares of Intellia Therapeutics worth $131K as of Q3 2026.
- Sigma Planning bought 751 Intellia Therapeutics shares in Q3 2026, an estimated $9.39K.
- Intellia Therapeutics made up ﹤0.01% of Sigma Planning's portfolio in Q3 2026, its #1288 holding.
- Sigma Planning first reported a position in Intellia Therapeutics in Q2 2025 and has held it in 3 quarters since.
- Sigma Planning's Intellia Therapeutics position peaked at $172K in Q2 2026.
- 239 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.
Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.